Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Revenues		$ 133,368	$ 245,160	$ 510,626	$ 487,119
Cost of revenues		21,505	52,193	71,965	101,538
Cost of revenues - related party		29,192	48,378	138,800	96,663
Gross profit		82,671	144,589	299,861	288,918
Operating expenses
General and administrative expenses		523,855	544,960	2,146,517	2,496,574
Salary and benefits		242,941	271,466	795,255	667,560
Advertising and marketing		251,330	720,531	1,332,957	1,633,528
Investor relations		255,000	255,500	438,000	774,965
Stock based compensation		567,619	151,592	1,881,464	1,367,134
Total operating expenses		1,840,745	1,944,049	6,594,193	6,939,761
Loss from operations		(1,758,074)	(1,799,460)	(6,294,332)	(6,650,843)
Other expense
Imputed interest - related party					(6,473)
Interest expense - amortization on discount		241,620		464,298
Total other expense		241,620		464,298	(6,473)
Loss before income taxes		(1,999,694)	(1,799,460)	(6,758,630)	(6,644,370)
Income taxes
Net loss		(1,999,694)	(1,799,460)	(6,758,630)	(6,644,370)
Net loss attributed to non-controlling interest		(461)		(837)
Net loss attributed to Mangoceuticals, Inc.		$ (1,999,233)	$ (1,799,460)	$ (6,757,793)	$ (6,644,370)
Basic and diluted loss per share
Basic loss per share		$ (0.99)	$ (1.70)	$ (3.83)	$ (6.68)
Diluted loss per share		$ (0.99)	$ (1.70)	$ (3.83)	$ (6.68)
Weighted average number of shares *
Basic	[1]	2,013,848	1,061,572	1,765,051	994,897
Diluted	[1]	2,013,848	1,061,572	1,765,051	994,897

[1] Shares and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split